1.91 USD
-0.02 (-1.04%)
1.94 USD
+0.03 (+1.57%)
Overall DRRX gets a fundamental rating of 2 out of 10. We evaluated DRRX against 191 industry peers in the Pharmaceuticals industry. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
DRRX had negative earnings in the past year.
DRRX had a negative operating cash flow in the past year.
DRRX had negative earnings in each of the past 5 years.
In the past 5 years DRRX always reported negative operating cash flow.
1.2 Ratios
DRRX has a Return On Assets (-27.86%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -99.86%, DRRX is in line with its industry, outperforming 41.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROIC | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DRRX's Gross Margin of 62.60% is fine compared to the rest of the industry. DRRX outperforms 70.56% of its industry peers.
In the last couple of years the Gross Margin of DRRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for DRRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
2. Health
2.1 Basic Checks
DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRRX has been increased compared to 1 year ago.
Compared to 5 years ago, DRRX has more shares outstanding
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -67.96, we must say that DRRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -67.96, DRRX is not doing good in the industry: 92.39% of the companies in the same industry are doing better.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.96 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
DRRX has a Current Ratio of 0.98. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of DRRX (0.98) is worse than 80.71% of its industry peers.
DRRX has a Quick Ratio of 0.98. This is a bad value and indicates that DRRX is not financially healthy enough and could expect problems in meeting its short term obligations.
DRRX has a Quick ratio of 0.95. This is in the lower half of the industry: DRRX underperforms 74.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
DRRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.61%, which is quite impressive.
Looking at the last year, DRRX shows a very negative growth in Revenue. The Revenue has decreased by -62.89% in the last year.
The Revenue for DRRX have been decreasing by -39.51% on average. This is quite bad
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
3.2 Future
Based on estimates for the next years, DRRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.95% on average per year.
DRRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.91% yearly.
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
5. Dividend
5.1 Amount
No dividends for DRRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.91
-0.02 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners22.34%
Inst Owner Change-95.74%
Ins Owners11.82%
Ins Owner Change-0.75%
Market Cap59.31M
Revenue(TTM)3.12M
Net Income(TTM)-3.48M
Analysts45.71
Price Target2.55 (33.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.78%
Min EPS beat(2)-9.24%
Max EPS beat(2)42.81%
EPS beat(4)3
Avg EPS beat(4)391.47%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)215.39%
EPS beat(12)10
Avg EPS beat(12)147.91%
EPS beat(16)13
Avg EPS beat(16)114.43%
Revenue beat(2)2
Avg Revenue beat(2)24.63%
Min Revenue beat(2)7.9%
Max Revenue beat(2)41.37%
Revenue beat(4)2
Avg Revenue beat(4)-9.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)41.37%
Revenue beat(8)3
Avg Revenue beat(8)-13.96%
Revenue beat(12)3
Avg Revenue beat(12)-15.73%
Revenue beat(16)5
Avg Revenue beat(16)-0.21%
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.01 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 17.03 | ||
| P/tB | 78.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.1
BVpS0.11
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% | ||
| FCFM | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score3
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.65% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | -67.96 |
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y32.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.28%
OCF growth 3YN/A
OCF growth 5YN/A
DURECT CORPORATION / DRRX FAQ
Can you provide the ChartMill fundamental rating for DURECT CORPORATION?
ChartMill assigns a fundamental rating of 2 / 10 to DRRX.
What is the valuation status of DURECT CORPORATION (DRRX) stock?
ChartMill assigns a valuation rating of 1 / 10 to DURECT CORPORATION (DRRX). This can be considered as Overvalued.
How profitable is DURECT CORPORATION (DRRX) stock?
DURECT CORPORATION (DRRX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for DRRX stock?
The Earnings per Share (EPS) of DURECT CORPORATION (DRRX) is expected to decline by -105.89% in the next year.